Kolumne, ORE

Original-Research: Borussia Dortmund GmbH & Co KGaA - von NuWays AG Einstufung von NuWays AG zu Borussia Dortmund GmbH & Co KGaA Unternehmen: Borussia Dortmund GmbH & Co KGaA ISIN: DE0005493092 Anlass der Studie: Update Empfehlung: BUY seit: 30.11.2023 Kursziel: EUR 5,50 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: Analyst: Philipp Sennewald Returning from Milan with pockets full of cash; chg.

30.11.2023 - 09:01:41

Original-Research: Borussia Dortmund GmbH & Co KGaA (von NuWays AG): BUY


Original-Research: Borussia Dortmund GmbH & Co KGaA - von NuWays AG

Einstufung von NuWays AG zu Borussia Dortmund GmbH & Co KGaA

Unternehmen: Borussia Dortmund GmbH & Co KGaA
ISIN: DE0005493092

Anlass der Studie: Update
Empfehlung: BUY
seit: 30.11.2023
Kursziel: EUR 5,50
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung: 
Analyst: Philipp Sennewald

Returning from Milan with pockets full of cash; chg.
 
On Tuesday, BVB visited AC Milan to play their penultimate Champions League
group stage match. Thanks to a 3-1 victory, the team has already qualified
for the knock-out stage before the last matchday, thus securing EUR 9.6m
additional premium payments on top of the EUR 2.8m for winning the match.
 
As Paris St. Germain only managed to get a draw (1-1) in their final home
game against Newcastle, BVB is now also in pole position finish first in
their group, as they only need a draw in the last match at home against
Paris. Mind you, BVB have not lost at home in the Champions League for two
years and overall lost only one out of the last 29 matches at Signal Iduna
Park. As the group winners play the second- placed team from another group
(i.e. an "easier" opponent) in the round of sixteen, this would clearly
improve BVB's chances to advance even to the quarterfinals, which would
secure another EUR 10.6m in premium payments (not reflected in our
estimates). Keep in mind, that those premium payments have a de facto 100%
margin, as no costs are incurred and that sales from ticketing, catering
and merchandising are not yet included in that number.
 
While the club is performing above expectations in the Champions League in
what we called an unlucky drawn group (Paris, Milan, Newcastle) back in
October, the Bundesliga performance appears somewhat lackluster so far as
BVB is only in 4th place after one third of the season. Although this would
be sufficient to qualify for the Champions League at the end of the season,
the team is seen to face tough competition from the surprisingly strong
Stuttgart (currently 3rd) and Leipzig (5th), while Leverkusen and Bayern
look set to decide the championship among themselves. Hence, BVB should be
competing with Stuttgart and Leipzig for the remaining two spots to qualify
for the CL. However, thanks to the depth and experience of the squad and
the fact that Stuttgart will have to withdraw several key players for the
Africa Cup and the Asian games in Q1, we regard BVB's chances for a Top-4
finish as high. Notably, this
will be more important than ever, as UEFA will introduce a new format
starting next season which will increase overall price money by c. 33%.
 
Valuation remains undemanding, in our view, as BVB shares are trading at
only 1.0x EV/Sales 2023/24, which marks a notable discount to its peers
Juventus (2.0x), OL (2.3x) and Manchester United (4.3x).
 
Reiterate BUY with an unchanged PT of EUR 5.50 based on DCF.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/28437.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.

Kontakt für Rückfragen
NuWays AG  - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. 
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

@ dpa.de

Weitere Meldungen

Original-Research: Nynomic AG (von Montega AG): Kaufen Original-Research: Nynomic AG - von Montega AG Einstufung von Montega AG zu Nynomic AG Unternehmen: Nynomic AG ISIN: DE000A0MSN11 Anlass der Studie: Update Empfehlung: Kaufen seit: 10.05.2024 Kursziel: 47,00 EUR (zuvor: 48,00 EUR) Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Miguel Lago Mascato Q1: Solider Jahresauftakt - Steigerung der ausgezeichneten H2/23-Performance & M&A-Newsflow erwartet Nynomic hat Mittwoch Q1-Zahlen veröffentlicht, die eine spürbare Steigerung ggü. (Boerse, 10.05.2024 - 16:16) weiterlesen...

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH)... Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to MPH Health Care AG Company Name: MPH Health Care AG ISIN: DE000A289V03 Reason for the research: Vorläufige Ergebnisse 2023 Recommendation: Kaufen from: 10.05.2024 Target price: EUR81 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. (Boerse, 10.05.2024 - 12:41) weiterlesen...

Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): ... Original-Research: Knaus Tabbert AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Knaus Tabbert AG Company Name: Knaus Tabbert AG ISIN: DE000A2YN504 Reason for the research: Dreimonatsbericht Recommendation: Kaufen from: 10.05.2024 Target price: EUR86 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG (ISIN: DE000A2YN504) veröffentlicht. (Boerse, 10.05.2024 - 11:46) weiterlesen...

Original-Research: ZEAL Network SE (von NuWays AG): Kaufen Original-Research: ZEAL Network SE - from NuWays AG Classification of NuWays AG to ZEAL Network SE Company Name: ZEAL Network SE ISIN: DE000ZEAL241 Reason for the research: Recommendation: Kaufen from: 10.05.2024 Target price: EUR 53.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Henry Wendisch Staggering Q1 kicks off new growth phase; chg est. (Boerse, 10.05.2024 - 09:07) weiterlesen...

Original-Research: Nynomic AG (von NuWays AG): Kaufen Original-Research: Nynomic AG - from NuWays AG Classification of NuWays AG to Nynomic AG Company Name: Nynomic AG ISIN: DE000A0MSN11 Reason for the research: Update Recommendation: Kaufen from: 10.05.2024 Target price: EUR 52.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Christian Sandherr Solid start into FY24 despite challenging end markets Topic: Nynomic published a solid start into the year with order intake returning to growth for the first time since Q3 2022. (Boerse, 10.05.2024 - 09:06) weiterlesen...

Original-Research: R. STAHL AG (von NuWays AG): Kaufen. STAHL AG - from NuWays AG Classification of NuWays AG to R. Original-Research: R. (Boerse, 10.05.2024 - 09:02) weiterlesen...